ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study

Li, Yiqun; Tong, Zhongsheng; Wu, Xinhong; Ouyang, Quchang; Cai, Li; Li, Wei; Yu, Zhiyong; Han, Zhengxiang; Wang, Xiaojia; Li, Man; Wang, Haibo; Li, Li; Yang, Jin; Niu, Zhaofeng; Wang, Qitang; Xu, Binghe*吉林大学; 青岛大学; 山东大学; 山东省医学科学院; 哈尔滨医科大学; 西安交通大学; 中国医学科学院; 中国科学院研究生院; 中国科学院; 中国医学科学院北京协和医院; 1
International Journal of Cancer2023-11-15DOI: 10.1002/ijc.34676
4阅读
引用收藏
分享

摘要

Pyrotinib, an irreversible pan-ErbB inhibitor, has been approved for treating HER2-positive advanced breast cancer in China. We conducted a nationwide, prospective observational study to examine the real-world data of pyrotinib-based therapy in this population. Patients from 61 sites across China were included. Pyrotinib-based regimens were prescribed at local physician's discretion. Demographics, treatment patterns, prognosis and safety were evaluated. The primary outcome was real-world progression-free survival (rwPFS). Of 1129 patients, pyrotinib-based therapy was prescribed as first-, second- and third- or later-line treatment in 437 (38.7%), 476 (42.2%) and 216 (19.1%) patients, respectively. Median rwPFS (mrwPFS) was 14.3 (95% CI, 13.3-15.2) months in the total population, with the longest mrwPFS of 17.8 (95% CI, 15.2-24.9) months in the first-line setting, followed by 14.4 (95% CI, 12.9-15.3) months in the second-line setting. Patients with third- or later-line treatment also achieved a mrwPFS of 9.3 (95% CI, 8.4-11.8) months. Patients with trastuzumab- or trastuzumab-pertuzumab-treated disease achieved a mrwPFS of 14.3 and 13.6 months, respectively. Dual HER2 blockade with pyrotinib plus trastuzumab showed a mrwPFS of 16.2 months in the total population, with data not mature in the first-line setting. For patients with baseline brain metastases, the mrwPFS was 11.7 months. The most common adverse event was diarrhea (any grade, 73.5%; grade = 3, 15.3%). In real world, pyrotinib-based therapy shows promising effectiveness in the first-, as well as second- and later-line treatment, with acceptable tolerability. Further investigations regarding front-line use or novel combinations of pyrotinib might facilitate to maximize its anti-tumor potential.

学科与关键词

关键词
breast cancerdiarrheahuman epidermal growth factor receptor 2pyrotinibreal-world
相关
加载中…
  • Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
    Xie, Yizhao; Li, Yi; Ting, Luo; Sang, Die; Yuan, Peng; Li, Wei; Li, Huihui; Ge, Rui*; Wang, Biyun*Frontiers in Oncology, 2021, 11: 699333.被引 4
  • Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
    Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Liu, Hu; Cheng, Ying; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Ye, Changsheng; Dong, Fangli; Wu, Shuchao; Zhu, Xiaoyu; Xu, Binghe*BRITISH MEDICAL JOURNAL, 2023, 383: e076065.被引 3
  • Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial
    Zheng, Yabing; Cao, Wen-Ming; Shao, Xiying; Shi, Yanxia; Cai, Li; Chen, Wenyan; Liu, Jian; Shen, Peng; Chen, Yiding; Wang, Xian; Li, Huiping; Li, Man; Chen, Zhanhong*; Wang, Xiaojia*Nature Communications, 2023, 14(1): 8314.
查看全部 →

发表信息

论文状态
公开发表
期刊
International Journal of Cancer
发表日期
2023-11-15
卷期
第 153 卷, 第 10 期
页码
1809-1818
DOI
10.1002/ijc.34676
语言
MULTI-LANGUAGE
成果收录
SCIE
资助标注
CAMS Innovation Fund for Medical Sciences (CIFMS) [2021-I2M-1-014]; Jiangsu Hengrui Pharmaceuticals Co., Ltd.

作者

  • L

    Li, Yiqun (第一作者)

    chinese acad med sci · peking union med coll

  • T

    Tong, Zhongsheng

    tianjin med univ

查看全部 16 位作者收起作者
  • W

    Wu, Xinhong

    hubei canc hosp

  • O

    Ouyang, Quchang

    hunan canc hosp

  • C

    Cai, Li

    harbin med univ

  • L

    Li, Wei

    1 · jilin univ

  • Y

    Yu, Zhiyong

    shandong acad med sci

  • H

    Han, Zhengxiang

    xuzhou med univ

  • W

    Wang, Xiaojia

    chinese acad sci, inst canc · chinese acad sci · univ chinese acad sci · zhejiang canc hosp

  • L

    Li, Man

    2 · dalian med univ

  • W

    Wang, Haibo

    qingdao univ

  • L

    Li, Li

    shandong univ

  • Y

    Yang, Jin

    1 · xi an jiao tong univ

  • N

    Niu, Zhaofeng

  • W

    Wang, Qitang

  • X

    Xu, Binghe (通讯)

    chinese acad med sci · peking union med coll

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417